Equity Profile

PCVX

Vaxcyte, Inc.

Health CareBiotechnology$8.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to protect against infectious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of a company's profitability and will indicate how well Vaxcyte is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth will provide insights into the company's market acceptance and demand for its vaccine products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to protect against infectious diseases. Operating in the health care sector, Vaxcyte's work is significant as it aims to address unmet medical needs through innovative vaccine solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, which was worse than the expected -$1.85. The stock reacted positively, gaining 2.62% the following day despite the miss.

Management Promises & Guidance

Focus on advancing vaccine candidates in clinical trials.
Commitment to reducing operational costs.
Plans to enhance partnerships for broader market reach.

Expectations

Wall Street Expectations

Overall, expectations for Vaxcyte's upcoming earnings are mixed, given the recent history of EPS misses and the lack of analyst estimates.

Bull Case

If Vaxcyte can surprise with better-than-expected EPS and demonstrate strong revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to show significant revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

The EPS figure will be crucial in assessing the company's financial health and could significantly influence stock performance.

What are the R&D expenses for this quarter, and how do they align with future growth plans?

Investors will closely watch R&D spending as it reflects Vaxcyte's commitment to innovation and future product development.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte to improve its EPS significantly this quarter, given its recent focus on cost management and strategic partnerships.

Supporting Evidence

The recent positive stock reaction despite EPS misses indicates some investor confidence.

Management's commitment to reducing operational costs could lead to better-than-expected EPS.

The options market is pricing a larger move than historical averages suggest, indicating potential for a surprise.

Key Risk

If R&D expenses come in lower than expected, it could suggest improved operational efficiency and support a bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings will be pivotal in determining whether Vaxcyte can turn around its recent performance and regain investor confidence.

Bull Confirmed If

An EPS of -$1.50 or better, along with a clear plan for future R&D investments.

Bear Confirmed If

An EPS worse than -$2.50, indicating continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests a modest positive reaction, potentially confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 0.06%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of vaccine candidates in clinical trials.
2Any updates on partnerships or collaborations that could enhance market reach.
3Insights into cost management strategies and their impact on future profitability.
4Clarification on R&D spending and its alignment with growth objectives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to protect against infectious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of a company's profitability and will indicate how well Vaxcyte is managing its costs and generating revenue.

N/A

Revenue Growth

Revenue growth will provide insights into the company's market acceptance and demand for its vaccine products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, which was worse than the expected -$1.85. The stock reacted positively, gaining 2.62% the following day despite the miss.

Management Promises & Guidance

Focus on advancing vaccine candidates in clinical trials.
Commitment to reducing operational costs.
Plans to enhance partnerships for broader market reach.

Expectations

Wall Street Expectations

Overall, expectations for Vaxcyte's upcoming earnings are mixed, given the recent history of EPS misses and the lack of analyst estimates.

Bull Case

If Vaxcyte can surprise with better-than-expected EPS and demonstrate strong revenue growth, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to show significant revenue growth, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

The EPS figure will be crucial in assessing the company's financial health and could significantly influence stock performance.

What are the R&D expenses for this quarter, and how do they align with future growth plans?

Investors will closely watch R&D spending as it reflects Vaxcyte's commitment to innovation and future product development.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte to improve its EPS significantly this quarter, given its recent focus on cost management and strategic partnerships.

Supporting Evidence

The recent positive stock reaction despite EPS misses indicates some investor confidence.

Management's commitment to reducing operational costs could lead to better-than-expected EPS.

The options market is pricing a larger move than historical averages suggest, indicating potential for a surprise.

Key Risk

If R&D expenses come in lower than expected, it could suggest improved operational efficiency and support a bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's earnings will be pivotal in determining whether Vaxcyte can turn around its recent performance and regain investor confidence.

Bull Confirmed If

An EPS of -$1.50 or better, along with a clear plan for future R&D investments.

Bear Confirmed If

An EPS worse than -$2.50, indicating continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests a modest positive reaction, potentially confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see limited movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with historical patterns suggesting an average drop of around 0.06%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of vaccine candidates in clinical trials.
2Any updates on partnerships or collaborations that could enhance market reach.
3Insights into cost management strategies and their impact on future profitability.
4Clarification on R&D spending and its alignment with growth objectives.